The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy-Reference-Cited by-同舟云学术

The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapy

Published:2020-06 Issue: Volume:210 Page:107517
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Palmieri L.-J.,Lavolé J.,Dermine S.,Brezault C.,Dhooge M.,Barré A.,Chaussade S.,Coriat R.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference103 articles.

1. LBA10_PRClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation;Abou-Alfa;Annals of Oncology,2019

2. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: A GERCOR study;André;Annals of Oncology,2004

3. Expert consensus document: Cholangiocarcinoma: Current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA);Banales;Nature Reviews. Gastroenterology & Hepatology,2016

4. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers;Bekaii-Saab;Journal of Clinical Oncology,2011

5. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor;Bendell;British Journal of Cancer,2017

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of PANoptosis-relevant subgroups and predicting signature to evaluate the prognosis and immune landscape of patients with biliary tract cancer;Hepatology International;2024-08-10

2. Extrachromosomal circular DNA (eccDNA) characteristics in the bile and plasma of advanced perihilar cholangiocarcinoma patients and the construction of an eccDNA-related gene prognosis model;Frontiers in Cell and Developmental Biology;2024-06-06

3. Bmi1 facilitates the progression of cholangiocarcinoma by inhibiting Foxn2 expression dependent on a histone H2A ubiquitination manner;Cancer Letters;2024-06

4. NLCECA score: a serum inflammatory-tumor biomarker score to predict survival of advanced perihilar cholangiocarcinoma after hepatic arterial infusion chemotherapy;Scientific Reports;2024-02-23

5. Preclinical evidence for preventive and curative effects of resveratrol on xenograft cholangiocarcinogenesis;Cancer Letters;2024-02